# NEPHSTROM for Diabetic Kidney Disease

> **NCT02585622** · PHASE1,PHASE2 · TERMINATED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 29 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **BIOLOGICAL:** Mesenchymal Stromal Cells
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02585622
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-11
- **Primary completion:** 2022-11-03
- **Final completion:** 2024-01-03
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** IMP NEPHSTROM ORBECEL-M is expired and additional extension is not feasible. Low recruitment rate at Birmingham center.
- **Last updated:** 2024-11-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585622, "NEPHSTROM for Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02585622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*